Chemomab-Scipher merger targets nebokitug RA readout with 2028 catalyst
Aug 19, 2026, 8:29 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
M&A activity can unlock value in small biotechs by creating a clearer path to capital markets (SCIP listing) and enabling pipeline collaborations. The CVR structure and large potential milestones (FDA PSC approval, Phase 3) provide optional upside while the RA readout in 2028 serves as a near-to-medium-term catalyst. Historical examples: small-cap biopharma mergers often re-rate near close when combined entities secure funding and clear development paths, though execution risk and financing terms can cap upside if milestones slip.
AI summary
What happened, with direct paths to the underlying reporting
Chemomab Therapeutics (CMMB) and Scipher Medicine have reached a definitive all-stock merger valued at $150 million pre-private placement, with a $30 million concurrent financing and CVRs. Nebokitug, a first-in-class anti-CCL24 antibody, is slated for a Phase 2 RA trial with topline results expected in H1 2028, offering potential value if efficacy materializes. The combined company would trade as SCIP on Nasdaq, with a cash runway through the Phase 2 readout, enhancing liquidity while disseminating ownership roughly 32% for Chemomab and 68% for Scipher.
Chemomab and Scipher announce definitive merger; combined value $150M pre-PP.
Nebokitug enters RA Phase 2; initiation in 1H2027; readout 1H2028.
post-close, combined company trades as SCIP; Chemomab holders ~32% ownership.
Cash runway through Phase 2 readout; $6.7M cash as of 6/30/2026.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
CMMB reported promising OLE results for nebokitug in PSC patients. Over 90% of trial patients opted for continued participation in the study. Nebokitug showed significant safety a…
